PT PHAPROS, TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 490 IDR | -1.21% |
|
-1.21% | -23.44% |
| 04-06 | PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PT Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 1,168B 72.45M 98.15M | Sales 2023 | 1,014B 62.88M 85.19M | Capitalization | 538B 33.33M 45.16M |
|---|---|---|---|---|---|
| Net income 2022 | 28.07B 1.74M 2.36M | Net income 2023 | 5.96B 369K 501K | EV / Sales 2022 | 1.09 x |
| Net Debt 2022 | 696B 43.14M 58.45M | Net Debt 2023 | 737B 45.68M 61.89M | EV / Sales 2023 | 1.26 x |
| P/E ratio 2022 |
20.5
x | P/E ratio 2023 |
90.2
x | Employees | 1,474 |
| Yield 2022 |
1.95% | Yield 2023 |
-
| Free-Float | 13.88% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.21% | ||
| 1 week | -1.21% | ||
| Current month | -5.77% | ||
| 1 month | -5.77% | ||
| 3 months | -4.85% | ||
| 6 months | -19.67% | ||
| Current year | -23.44% |
1 week
490.00
510.00
1 month
484.00565.00
Current year
484.00665.00
1 year
484.001 000.00
3 years
484.001 550.00
5 years
484.002 970.00
10 years
484.003 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hadi Kardoko
CEO | Chief Executive Officer | 47 | 20-05-31 |
David Sidjabat
DFI | Director of Finance/CFO | - | 21-05-26 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 08-03-31 | |
| Director/Board Member | 51 | 21-05-26 | |
| Chairman | - | 21-05-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 490 | -1.21% | 157,600 |
| 24-04-26 | 496 | 0.00% | 47,300 |
| 24-04-25 | 496 | -0.40% | 106,400 |
| 24-04-24 | 498 | +0.40% | 56,200 |
| 24-04-23 | 496 | 0.00% | 1,968,900 |
End-of-day quote INDONESIA S.E., April 28, 2024
More quotes
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.
Sector
Pharmaceuticals
Calendar
2024-06-30
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.44% | 25.68M | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
- Stock Market
- Equities
- PEHA Stock
